MedTrace Logo

Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients

NCT06225206 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-03-28

No results posted yet for this study

Summary

Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS). Based on this range use the dd-cfDNA levels to determine over or under IS in liver transplant patients to make changes to their IS medication regimen.

Conditions

  • Liver Transplant Failure

Interventions

BEHAVIORAL

donor-derived cell free DNA in liver

Determine the difference in age, gender, LFTs, IS regimen (tacrolimus/sirolimus/cyclosporin with mycophenolate mofetil (MMF) and /or prednisone) between patients who underwent liver transplant \<1 year PTX and \>1 year PTX

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Parvez Mantry, MD · Methodist Midlothian Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06225206 on ClinicalTrials.gov